Oscar Health Inc.
Oscar Health Inc. (OSCR): 3 upcoming catalysts · ~30 mo cash runway · 94 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
29.8 months
D/E 4.58
N/A
N/A
3 upcoming, next in ~348d
1 buy · 23 sells (180d)
A transparent, data-derived signal for Oscar Health Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$8.6B
Cash
$4.8B
Quarterly Burn
$706.2M
Runway
29.8 mo
Revenue
$4.6B
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Upcoming Catalysts (3)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
330
Total value held
$2.09B
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 21,555,254 | $247.2M |
| blackrock, inc. | 17,309,539 | $198.5M |
| vanguard portfolio management llc | 10,545,848 | $121.0M |
| susquehanna international group, llp | 9,652,604 | $110.7M |
| citadel advisors llc | 7,792,362 | $89.4M |
| american century companies inc | 7,029,356 | $80.6M |
| d. e. shaw & co., inc. | 6,570,785 | $75.4M |
| jane street group, llc | 6,428,205 | $73.7M |
| state street corp | 5,262,372 | $60.4M |
| geode capital management, llc | 5,032,255 | $57.7M |
Showing top 10 of 330 institutional holders of Oscar Health Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
What is Oscar Health Inc.'s next catalyst?
Oscar Health Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: Phase III Randomised Trial Evaluating Treatment Intensification With Temozolomide in Adults With a G" — expected June 1, 2027.
What is Oscar Health Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Oscar Health Inc. has approximately 29.8 months of cash runway.
What is Oscar Health Inc.'s market capitalization?
Oscar Health Inc.'s market capitalization is approximately $8.6B.
Who is the CEO of Oscar Health Inc.?
Mr. Mark Thomas Bertolini is the chief executive officer of Oscar Health Inc. (OSCR).
Get the full picture on Oscar Health Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.